INTRODUCTION
============

Regulation of ion channels and transporters by the signaling lipid phosphoinositide 4,5-bisphosphate (PI(4,5)P~2~) was first recognized by [@bib17] nearly 20 yr ago. Since that time, a growing number of channels and transporters have been found to be regulated by PI(4,5)P~2~, including voltage-gated K^+^, Ca^2+^, and Na^+^ channels, inward-rectifier K^+^ channels, two-pore domain K^+^ channels, Ca^2+^ release channels, P2X channels, TRP channels, and the NCX, NHE, NME, and PMCA families of transporters (reviewed in [@bib45]; [@bib11]). As essential as PI(4,5)P~2~ appears to be for regulating channels and transporters, the mechanism by which it does so is unknown.

Two broad classes of phosphoinositide-binding domains have been described. Pleckstrin homology (PH) domains typify one class (reviewed in [@bib48]; [@bib24], [@bib25]). They form highly organized networks of hydrogen bonds between the phosphoinositide head group and a structured binding pocket. The canonical protein--ligand interaction allows them to discriminate among phosphoinositides. For example, the PH domain from general receptor for phosphoinositides, isoform 1 (Grp1) shows a 160-fold higher affinity for PI(3,4,5)P~3~ compared with PI(3,4)P~2~ and immeasurably low affinity for PI(4,5)P~2~ ([@bib10]), although it should be noted that such extreme selectivity is probably the exception rather than the rule ([@bib25]).

A second class of phosphoinositide-binding domains is typified by a polybasic region within the protein myristoylated alanine-rich C kinase substrate (MARCKS; [@bib1]; [@bib51]). The PI(4,5)P~2~-binding domain of MARCKS includes basic residues that interact electrostatically with anionic lipids. The high charge density of PI(4,5)P~2~ compared with PI(4)P or phosphatidylserine confers nominal selectivity to the polyphosphorylated phosphoinositide, but no stereoselectivity has been observed.

The phosphoinositide selectivity of inward rectifier K^+^ channels is perhaps the best studied among ion channels. K~ATP~ channels are essentially nonselective such that the anionic fatty acid acyl-CoA can effectively substitute for PI(4,5)P~2~ ([@bib41]). In contrast IRK1 is selective for PI(4,5)P~2~ over PI(3,4,5)P~3~ and other forms of PIP~2~ ([@bib40]). The crystal structure of GIRK2 bound to PI(4,5)P~2~ shows a structured binding pocket in which several hydrogen bonds are formed between basic residues in the protein and both the 4′ and 5′ phosphates ([@bib52]). Based on this structure, it seems reasonable to predict that GIRK2 might display some phosphoinositide selectivity. Unfortunately, the selectivities of GIRK1 and GIRK2 channels for phosphoinositides have not yet been reported. In summary, even where structural information is now available, the mechanism for discriminating among phosphoinositides is unknown.

TRPV1 is a ligand-gated nonselective cation channel that was first cloned as the receptor for the pungent vanilloid compound capsaicin ([@bib6]). Since then it has been shown that TRPV1 is a multimodal receptor that can be activated by capsaicin and other natural irritants, noxious heat, acidity, and a variety of lipids including phosphoinositides and anandamide (*N*-arachidonoylethanolamine, an endocannabinoid; reviewed in [@bib2]). TRPV1 is expressed largely, albeit not uniquely, in peripheral sensory neurons where it is thought to be involved in mediating both noninflammatory thermal and chemical pain, as well as thermal and chemical hyperalgesia ([@bib53]; [@bib7]; [@bib32]). Indeed, TRPV1 knockout mice show a diminished sensitivity to chemical and thermal noxious stimuli, in addition to greatly diminished inflammatory hyperalgesia ([@bib7]). More recently, TRPV1 has been proposed as a candidate target for therapeutic approaches besides analgesia, i.e., cough, asthma, and itch suppression ([@bib22]; [@bib3]; [@bib38]; [@bib39]).

Although it is widely agreed that regulation of TRPV1 gating by PI(4,5)P~2~ plays an important role in regulating the response of pain receptor neurons to noxious stimuli, disagreement about whether PI(4,5)P~2~ activates or inhibits TRPV1 continues ([@bib8]; [@bib37]; [@bib44]; [@bib28], [@bib29]; [@bib47]; [@bib4],[@bib5]; [@bib42]). There is also disagreement about whether PI(4,5)P~2~ interacts directly with TRPV1 or acts via the integral membrane protein Pirt ([@bib21]; [@bib47]). Finally, several regions of TRPV1 have been proposed for mediating the interaction with PI(4,5)P~2~, some of which are illustrated in [Fig. 1 A](#fig1){ref-type="fig"}. This cartoon depicts the backbone of TRPV1 as determined from cryo-electron microscopy studies ([@bib4],[@bib5]). WT TRPV1 is composed of 868 amino acids. However, to improve stability of the purified protein, amino acids 1--109, 604--626, and 765--838 were eliminated from the construct. In addition, amino acids 503--507 in the S2--S3 loop and 720--751 in the proximal C-terminal region, although present in the protein, could not be resolved. PI(4,5)P~2~ has been proposed to inhibit TRPV1 by binding to amino acids 777--820 in the distal C-terminal region ([@bib37]) and to activate TRPV1 by binding to the proximal C-terminal region represented by amino acids 682--725 ([Fig. 1 A](#fig1){ref-type="fig"}, magenta; [@bib47]). In addition, mutations in the ankyrin repeat domains appear to abrogate PI(4,5)P~2~ depletion--mediated desensitization of TRPV1, although a direct interaction between PI(4,5)P~2~ and a fragment corresponding to the ankyrin repeat domain was not observed ([@bib27]). The proximal C-terminal region appears to be positioned close to the bilayer--solution interface ([Fig. 1 A](#fig1){ref-type="fig"}), making this region especially interesting as a candidate PI(4,5)P~2~-binding site.

![Proposed PI(4,5)P~2~-binding sites in TRPV1 and GIRK2. (A) Regions shown to be important for PI(4,5)P~2~ regulation mapped onto the apo-state structure of TRPV1 (PDB ID: [3J5P](3J5P)). One of the four subunits is shown primarily in blue, with S6 in cyan, the helix following S6 in magenta, and the region following this helix shown in dark gray. The approximate position of R721 is indicated by the blue circle. The red circle represents a phosphoinositide head group. Likely membrane position is denoted by dashed lines. (B) Amino acids implicated in PI(4,5)P~2~ modulation of GIRK2 channels, based on functional experiments, mapped onto the tetrameric Kir3.2 structure (PDB ID: [3SYA](3SYA)). Amino acids as discussed in [@bib54] are shown as ball and sticks colored in CPK. The assigned diC8-PI(4,5)P~2~ from the structure is shown as cyan sticks.](JGP_201511354_Fig1){#fig1}

Identification of the region of primary sequence of TRPV1 that interacts directly with PI(4,5)P~2~ has remained elusive as a result of the few approaches that provide definitive information. The inward rectifier Kir ion channels provide a useful illustration. Based on electrophysiological interrogation of several engineered point mutations, a large number of residues, scattered throughout the cytoplasmic region, had been proposed to be involved in PI(4,5)P~2~ regulation ([@bib54]). These residues are mapped onto the crystal structure of the Kir3.2 channel in [Fig. 1 B](#fig1){ref-type="fig"} (residues in question shown as ball and stick; structured diC8-PI(4,5)P~2~ in cyan). Many of the amino acids face the interior of the protein, and most are not expected to be in close proximity with the surface of the bilayer. Thus, although site-directed mutagenesis was successful in identifying basic residues located near where the PI(4,5)P~2~ head group is expected to be, the false-positive rate of this approach was very high.

An approach that has been used to successfully identify amino acids that interact with ligands is a form of thermodynamic mutant cycle analysis in which functional analysis of a channel is performed on WT channel and on a channel with a point mutation for both the ligand of choice and a structurally similar analogue. This approach was applied to cyclic nucleotide--gated channels that are selective for cGMP over cAMP ([@bib50]; [@bib13]). However, a point mutation inverted the selectivity, making the channels selective for cGMP over cAMP. For the mutation to invert the selectivity, it was reasoned that the residue in question must be able to "tell the difference" between the two, related ligands. The simplest explanation for such a change in selectivity is that the mutated residue is in a region that interacts with the parts of the two ligands that are different. Indeed, once the structures of cyclic nucleotide--binding domains of several cyclic nucleotide--gated channels were determined with x-ray crystallography, the amino acid that inverted the selectivity was found to interact with the atoms of the cyclic nucleotide purine rings that differ between cGMP and cAMP ([@bib56]; [@bib12]; [@bib55]).

We took a similar approach to localize a direct interaction between TRPV1 ion channels and PI(4,5)P~2~. We measured dose--response relations for activation of TRPV1 by either PI(4,5)P~2~ or PI(4)P, which differ at only the 5′ position of the inositol ring. WT TRPV1 is selective for PI(4,5)P~2~ over PI(4)P, with an EC~50~ value ∼30-fold higher for PI(4)P. We found that a single point mutation in the proximal C-terminal region inverted the selectivity such that the EC~50~ value for PI(4)P was approximately sixfold lower than that for PI(4,5)P~2~. Using thermodynamic mutant cycle analysis, we found a coupling energy between the side chain at position 721 of TRPV1 and the moiety on the 5′ position of phosphoinositide inositol ring of ∼3 kcal/mol, indicating a likely direct interaction. The inverted selectivity allowed PI(4)P to support activation of TRPV1 by capsaicin even upon depletion of PI(4,5)P~2~ by a voltage-activated or chemically induced inositol 5 phosphatase. Together, our data rule out a diffuse electrostatic mechanism for interaction between phosphoinositides and TRPV1 and point to a selective binding pocket in the proximal C-terminal region including R721.

MATERIALS AND METHODS
=====================

Cell culture
------------

F-11 cells were cultured at 37°C, 5% CO~2~, in Ham's F12 nutrient mixture (Invitrogen) supplemented with 20% fetal bovine serum, HAT supplement (100 µM sodium hypoxanthine, 400 nM aminopterin, and 16 µM thymidine) and penicillin/streptomycin. For electrophysiology experiments, cells were grown in 12-mm glass coverslips and transfected with Lipofectamine 2000 (Life Technologies) according to the manufacturer's instructions. They were used for experimentation 12--48 h after transfection.

HEK 293T/17 cells were cultured at 37°C, 5% CO~2~, in Dulbecco's modified Eagle's medium (Invitrogen) containing 25 mM glucose, 1 mM sodium pyruvate, and 4 mM [l]{.smallcaps}-glutamine. Culture medium was supplemented with 10% fetal bovine serum and penicillin/streptomycin. For simultaneous electrophysiology and imaging experiments, cells were transfected using Lipofectamine 2000 according to the manufacturer's instructions. 12 h after transfection, cells were placed on 25-mm glass coverslips (coated with polylysine to aid cell attachment) and left in culture until used for experimentation 12--36 h after.

Molecular biology
-----------------

The cDNA for rat TRPV1 was provided to us by D. Julius (University of California, San Francisco, San Francisco, CA). Ci-VSP.pIRES2-EGFP was a gift from Y. Okamura (Osaka University, Suita, Osaka, Japan). B. Hille (University of Washington, Seattle, WA) shared with us the rapamycin-inducible phosphatase expression system: CFP-FKBP-InsP (fusion of a 5′-phosphatase and the dimerizing domain from FK506-binding protein \[FKBP\]) and LDR-FRB (membrane-anchored dimerizing receptor for FKBP; [@bib46]). PH-YFP is an abbreviation for YFP-PLCδ1-PH, given to us by T. Balla (National Institutes of Health, Bethesda, MD). TRPV1-R721A.pcDNA3 was generated by subcloning from TRPV1-R721A-eYFP.pcDNA3 (not used in this study), which was previously created using two-step PCR. In the first step, the point mutation was introduced by overlapping primers containing the Ala mutation. The second step regenerated a partial TRPV1 sequence containing the R721A sequence for subsequent subcloning into a TRPV1-eYFP.pcDNA3 vector (where e-YFP is fused to the C terminus of the insert). Then, the region containing the R721A mutation was excised from TRPV1-R721A-eYFP.pcDNA3 and inserted into the equivalent region of TRPV1.pcDNA3. The new construct was screened by restriction digest analysis.

Phosphoinositides and polylysine
--------------------------------

The short-chain versions of PI(4,5)P~2~ and PI(4)P (containing 8-carbon tails in place of the naturally occurring fatty acids) were purchased from Avanti Polar Lipids, Inc. Phosphoinositides were solubilized in a Ca^2+^-free solution (containing, in mM: 130 NaCl, 3 HEPES, and 0.2 EDTA, pH 7.4) as 1 mM stocks and kept at −20°C until the day of experiments, when dilutions to the working concentrations needed were prepared. Right before experiments, working solutions were sonicated using a G112SP1 Special Ultrasonic Cleaner (Laboratory Supplies Company). Polylysine (70--150 kD) was solubilized as a 1.2 mg/ml stock, aliquoted, and kept at −20°C. The day of experiments, one aliquot was thawed and diluted to the working concentration (15 µg/ml). All other chemicals were purchased from Sigma-Aldrich.

Inside-out excised patch experiments
------------------------------------

Currents were recorded at room temperature using filamented borosilicate glass pipettes heat polished with a microforge (3.5--4.5 MΩ). External and internal solutions were the same within each recording. For voltage-sensitive phosphatase (VSP) experiments the solutions used were, in mM: 130 NaCl, 3 HEPES, and 0.2 EDTA, pH 7.4. To obtain the phosphoinositide dose--response relationships, the HEPES concentration was increased to 10 mM. Coverslips containing cells were placed on a 12-mm open configuration chamber. Except where indicated, excised patches were held at 0 mV and stepped between −100 and 100 mV to drive currents. Solutions were delivered to the cytosolic-facing side of the membrane patch by positioning the recording pipette in front of an open tube in a "sewer pipe" configuration of several tubes assembled on a headstage controlled by a RSC-200 solution-exchange manifold (Bio-Logic Science Instruments). Phosphoinositide dose--response relationships and single channel currents were recorded using an EPC-10 amplifier (HEKA). VSP experiments were performed using an Axon 200B amplifier (Axon Instruments). Both amplifiers were controlled by Pulse (v. 8.8; HEKA) on a Dell personal computer. Capsaicin was prepared as a 10 mM stock in ethanol, kept at 4°C, and diluted to 1 µM in recording saline solution on the day of experiments. Within each experiment, the same 1 µM capsaicin solution was used to dilute all other working solutions. All currents shown are capsaicin-activated currents; i.e., the current in vehicle solution was subtracted from the current measured after capsaicin stimulation.

Simultaneous perforated patch whole-cell voltage clamp and confocal imaging
---------------------------------------------------------------------------

Experiments were performed at room temperature as previously described ([@bib23]). In brief, filamented borosilicate glass pipettes heat polished with a microforge (3.0--4.0 MΩ) were filled with intracellular saline solution containing (in mM) 110 potassium aspartate, 30 KCl, 10 NaCl, 1 MgCl~2~, 0.05 EGTA, and 10 HEPES, pH 7.2, and 1 mg/ml amphotericin-B. Cells were continuously perfused in Hank's buffered salt solution (in mM): 140 NaCl, 4 KCl, 1 MgCl~2~, 1.8 CaCl~2~, 5 glucose, and 10 HEPES, pH 7.4, until achieving perforation. At this point the external solution was switched to a nominally Ca^2+^-free solution containing (in mM): 140 NaCl, 4 KCl, 2 MgCl~2~, 5 glucose, and 10 HEPES, pH 7.4. All stimuli were added in this solution. Currents were recorded using a MultiClamp 700A amplifier (Axon Instruments) controlled with Clampex 8.2 in a Dell personal computer. All currents shown are capsaicin-activated currents (see above). Confocal images were obtained using a Radiance-2100 system (Bio-Rad Laboratories) controlled with proprietary software and coupled to a Nikon TE300 inverted microscope (Nikon ×60 oil immersion objective, numerical aperture = 1.4). The 488-nm line of an argon laser was used to excite PH-YFP, and the emission from 500--525 nm was collected. Images were analyzed with MetaMorph 7.0 (Molecular Devices) and ImageJ (National Institutes of Health).

Data analysis and statistics
----------------------------

All data were analyzed using Igor Pro 6 (WaveMetrics). Box plots were prepared as follows: boxes represent the range of data from the 25th to 75th percentiles, whiskers represent the data range from the 10th to 90th percentiles, and horizontal lines represent the median. The values given as errors within the text and in figures represent the SEM. A two-tailed Mann--Whitney *U* test (see [Fig. 4](#fig4){ref-type="fig"}; <http://www.socscistatistics.com>) or two-tailed Student's *t* test (see [Fig. 5](#fig5){ref-type="fig"}; Microsoft Excel) was used to determine statistical significance when the distributions were not or were normal, respectively.

RESULTS
=======

A mutation of arginine 721 to alanine inverts the phosphoinositide selectivity of TRPV1
---------------------------------------------------------------------------------------

To determine whether the PI(4,5)P~2~-binding site previously identified in TRPV1 in vitro mediates PI(4,5)P~2~ regulation of TRPV1, we tested for mutations in the proximal C-terminal region (amino acids 682--725; [Fig. 1 A](#fig1){ref-type="fig"}) that altered the phosphoinositide selectivity of the channels by comparing activation by PI(4,5)P~2~ with activation by PI(4)P. PI(4)P naturally occurs in the plasma membranes of mammalian cells at concentrations similar to PI(4,5)P~2~, and it is identical to PI(4,5)P~2~ except at the 5′ position of the inositol ring, where there is a hydroxyl instead of a phosphate.

We measured dose--response relations for water-soluble diC8-PI(4,5)P~2~ ([Fig. 2 A](#fig2){ref-type="fig"}) and diC8-PI(4)P ([Fig. 2 B](#fig2){ref-type="fig"}) applied to inside-out patches via the bath in the presence of 1 µM capsaicin, after first treating the patches with PolyK ([@bib34]) to sequester native anionic lipids. We used transient transfection of WT TRPV1 (TRPV1-WT) cDNA in F-11 cells, a hybridoma between rat dorsal root ganglion neurons and mouse neuroblastoma cells. The dose--response relations for activation of TRPV1 by diC8-PI(4,5)P~2~ and diC8-PI(4)P were plotted for each patch and fit with the Hill equation, with the maximum current (I~max~) as a free parameter. The currents for each patch were then normalized to the I~max~ value obtained from the fit for the patch, and the data from multiple patches were pooled to determine a mean and SEM, shown in [Fig. 2 D](#fig2){ref-type="fig"}. As we have previously shown, the apparent affinity of TRPV1 for diC8-PI(4,5)P~2~ ([Fig. 2 D](#fig2){ref-type="fig"}, closed red circles) was greater than that for diC8-PI(4)P ([Fig. 2 D](#fig2){ref-type="fig"}, closed blue circles; [@bib23]), with EC~50~ solution concentrations of 0.68 µM and 21 µM diC8-PI(4,5)P~2~ and diC8-PI(4)P, respectively (Hill slope, n~H~, fixed at 2 for both fits).

![The single-point mutation R721A inverts the selectivity of TRPV1 for PI(4,5)P~2~ and PI(4)P. (A) Current traces for activation of TRPV1-R721A channels by PI(4,5)P~2~ at the indicated concentrations. (B) Current traces for activation of TRPV1-R721A by PI(4)P. (A and B) 1 µM capsaicin was present for all measurements except for the current shown as the dotted trace, which is the leak current in the absence of capsaicin. This leak current was not subtracted from the other traces. The voltage protocol involved holding patches at 0 mV, followed by voltage jumps to −100 mV and 100 mV, followed by a return to 0 mV. PolyK was applied to the patch before acquisition of traces shown. (C) Capsaicin dose--response curves for TRPV1-WT (solid line and closed circles) and TRPV1-R721A (dashed line and open circles). For TRPV1-WT, the EC~50~ value was 79.5 nM (n~H~ = 1, *n* = 4--5 patches). For TRPV1-R721A, the EC~50~ value for capsaicin was 330 nM (n~H~ = 1, *n* = 4). (D) Normalized current in TRPV1-WT (solid, closed) and TRPV1-R721A (dashed, open) versus solution concentration of PI(4,5)P~2~ or PI(4)P. For TRPV1-WT, the EC~50~ values were 0.68 µM (*n* = 4--7 patches) and 20.9 µM (*n* = 5 patches) for PI(4,5)P~2~ and PI(4)P, respectively, and n~H~ values obtained from the Hill fits were 2 for both curves. For TRPV1-R721A, EC~50~ values were 0.88 µM (n~H~ = 2, *n* = 3--5) and 0.144 µM (n~H~ = 2, *n* = 4) for PI(4,5)P~2~ and PI(4)P, respectively. (E) Same as D, but the data and fitted model are plotted versus mole fraction of lipids in the plasma membrane cytosolic leaflet. (C--E) SEM is shown.](JGP_201511354_Fig2){#fig2}

In our search for point mutations that alter phosphoinositide selectivity, we focused on the first 40 or so amino acids following S6, as we reasoned that the conserved function of regulation by phosphoinositides among TRP channels would reside in a region of conserved sequence. Outside of the transmembrane domain core, the first ∼40 amino acids following the last transmembrane domain represent the only conserved sequence among TRPC, TRPM, and TRPV channels. In addition, we have previously shown that a peptide derived from this region interacts with PI(4,5)P~2~ in vitro ([@bib47]).

We identified a single point mutation, R721A, that inverted the selectivity of TRPV1, so that less PI(4)P ([Fig. 2 B](#fig2){ref-type="fig"}) was required to activate TRPV1-R721A than PI(4,5)P~2~ ([Fig. 2 A](#fig2){ref-type="fig"}). Dose--response relations were measured for both phosphoinositides and indicated that apparent affinity of TRPV1-R721A for diC8-PI(4)P ([Fig. 2 D](#fig2){ref-type="fig"}, open blue circles) was greater than that for diC8-PI(4,5)P~2~ ([Fig. 2 D](#fig2){ref-type="fig"}, open red circles). Fitting these data will the Hill equation gave an EC~50~ value for activation of R721A channels by diC8-PI(4)P of 0.14 µM and for activation by diC8-PI(4,5)P~2~ of 0.88 µM. This represents a 1.3-fold increase in the EC~50~ value for diC8-PI(4,5)P~2~ but a 150-fold decrease in the EC~50~ value for diC8-PI(4)P. The R721A mutation might not have been notable if we had examined only diC8-PI(4,5)P~2~. By screening mutants against both diC8-PI(4,5)P~2~ and diC8-PI(4)P, we identified a single point mutation that produced an effect of more than two orders of magnitude for one ligand but only a small effect on the other. Given that PI(4)P and PI(4,5)P~2~ are different only at the 5′ position on the inositol ring, we hypothesized that the amino acid at position 721 interacts directly with the hydroxyl or phosphate group at the 5′ position of PI(4)P or PI(4,5)P~2~, respectively.

Although a point mutation that alters the selectivity for related agonists is likely to reside within the agonist-binding site, it may produce additional, nonlocal effects of channel gating that may be masked by the inverted agonist selectivity. To determine whether the R721A mutation produced nonspecific effects of channel gating and to measure their amplitude, we measured dose--response relations for activation of TRPV1-WT ([Fig. 2 C](#fig2){ref-type="fig"}, closed symbols; *n* = 4--5 patches) and TRPV1-R721A ([Fig. 2 C](#fig2){ref-type="fig"}, open symbols; *n* = 4 patches) by capsaicin in the presence of native lipids in the patch (no polyK treatment). Fitting these data with the Hill equation gave Hill slopes of 1 for both datasets and EC~50~ values of 79.5 nM and 330 nM for TRPV1-WT and TRPV1-R721A, respectively. The decrease in apparent affinity of TRPV1-R721A channels compared with TRPV1-WT suggests that the mutation produced a small, inhibitory effect on channel gating. Because R721 is distant from the proposed capsaicin-binding site ([@bib20]), the inhibitory effect of the mutation on gating by capsaicin likely represents a nonlocal, nonspecific effect on gating rather than a direct effect on the capsaicin-binding site. It is important to note that this nonspecific effect is likely convolved with the phosphoinositide-specific effects observed in [Fig. 2 D](#fig2){ref-type="fig"}. Thus, the apparent lack of effect of the R721A mutation on the apparent affinity for PI(4,5)P~2~ could arise from the combination of nonspecific inhibition of gating and potentiation of activation by PI(4,5)P~2~. Because the nonspecific effects on gating are expected to be the same for activation by PI(4)P and PI(4,5)P~2~, they can be disregarded when comparing the effects of the mutation on the two phosphoinositides.

To further probe whether the effects of the R721A mutation on phosphoinositide selectivity were caused by nonspecific allosteric effects or by a direct interaction of R721 with PI(4,5)P~2~, we performed thermodynamic mutant cycle analysis. This approach, developed by Fersht, compares differences in ΔG (ΔΔG) for a perturbation under two different conditions ([@bib19]; [@bib43]). In our case, we can calculate the ΔΔG for mutant versus WT channels (ΔΔG~WT\ mutant~) with two different phosphoinositides, PI(4)P and PI(4,5)P~2~. First, the EC~50~ from the phosphoinositide dose--response relations were taken as reasonable estimates of *K*~d~ and used to calculate ΔG = −RTln(*K*~d~), although it should be noted that the Hill slope of 2 used to fit the dose--response relations in [Fig. 2 D](#fig2){ref-type="fig"} made the EC~50~ only an estimate of *K*~d~. The difference between calculated ΔG values for a given phosphoinositide in the WT and mutant was taken as ΔΔG~WT\ mutant~. A mutation outside the phosphoinositide-binding site may well produce changes in the free energy of activation, but these changes should be the same whether activation is produced by PI(4)P or by PI(4,5)P~2~. Thus, the calculated difference between ΔΔG~WT\ mutant~ for PI(4)P and ΔΔG~WT\ mutant~ for PI(4,5)P~2~ (ΔΔΔG) should be close to zero. In contrast, mutation of an amino acid that directly contacts the phosphoinositide may produce a large ΔΔΔG. Quantitatively, if ΔΔΔG \> 0.5 kcal/mol, the changes in amino acid sequence and the changes in the phosphoinositide are said to be energetically coupled ([@bib16]; [@bib18]; [@bib35]). The difference between ΔΔG~WT-R721A~ for PI(4,5)P~2~ (0.15 kcal/mol) and ΔΔG~WT-R721A~ for PI(4)P (−3.0 kcal/mol) is 3.1 kcal/mol, well above the 0.5 kcal/mol threshold for coupling, as illustrated in [Fig. 3](#fig3){ref-type="fig"}. The simplest interpretation of this analysis is that the moiety at the 5′ position of the phosphoinositide inositol ring interacts directly with the side chain of amino acid 721 in TRPV1.

![Thermodynamic mutant cycle analysis for TRPV1-WT versus TRPV1-R721A (down arrows) and PI(4,5)P~2~ versus PI(4)P (horizontal arrows). Values were calculated using the equation ΔG = −RTlnK, where the EC~50~ for activation by phosphoinositide was used as an approximation for K.](JGP_201511354_Fig3){#fig3}

Depletion of PI(4,5)P~2~ by a VSP inhibits TRPV1-WT and TRPV1-R721A to different levels in inside-out excised patches
---------------------------------------------------------------------------------------------------------------------

To our knowledge, a point mutation that inverts the selectivity of a phosphoinositide-binding domain is unprecedented (but see [@bib36]) and offered a unique window into the mechanism of phosphoinositide selectivity. However, we were concerned that the measured differences between the apparent affinity for PI(4)P and PI(4,5)P~2~ could have been caused by the short acyl chains (C8), which were used here to enhance the phosphoinositide solubility in water and allow multiple phosphoinositide concentrations to be applied to each patch. To address this concern, we used a voltage-inducible phosphoinositide phosphatase to decrease the native PI(4,5)P~2~ in the plasma membrane and generate PI(4)P. If, for TRPV1-R721A channels, PI(4)P is indeed a better agonist than is PI(4,5)P~2~, then TRPV1-R721A channels might be bound to PI(4)P at rest, and instead of leading to inhibition of TRPV1 activation, conversion of PI(4,5)P~2~ to PI(4)P by the inducible phosphatase would be expected to have little or no effect.

We tested the prediction that the effect of conversion of PI(4,5)P~2~ to PI(4)P using a VSP would be reduced in TRPV1-R721A compared with WT TRPV1. We coexpressed VSP from the tunicate *Ciona intestinalis* with TRPV1 ([@bib33]) and examined the capsaicin-activated currents in inside-out excised patches ([Fig. 4](#fig4){ref-type="fig"}). Using excised patches was critical, as it has been previously shown in HEK293 cells examined with whole-cell patch-clamp that VSP activation is insufficient to deplete PI(4,5)P~2~ below the threshold for activation of TRPV1, albeit using another species of VSP ([@bib30]). In addition to removing the channels from many cellular enzymes, patch excision allowed us to perform our experiments in the absence of ATP, so that new synthesis of PI(4)P and PI(4,5)P~2~ by lipid kinases did not occur. The VSP was activated by depolarizing steps to 100 mV, separated by short steps to 0 mV to preserve the integrity of the patch and steps to −60 mV to measure inward currents ([Fig. 4 A](#fig4){ref-type="fig"}, inset).

![Conversion of PI(4,5)P~2~ to PI(4)P by a VSP inhibits TRPV1-WT with little or no inhibition of TRPV1-R721A in inside-out excised patches. (A) Representative time course measurements for currents in inside-out excised patches of cells transfected with TRPV1-WT or TRPV1-R721A alone (left) or in combination with VSP (right). The dotted lines represent zero current. The bars above the current indicate when capsaicin was added. For each experiment, 1 µM capsaicin was added to cells held at a potential of −60 mV during the time indicated by the red bar. Once current activation had reached steady-state, defined as time = 0 and denoted by the arrows, the voltage protocol shown in the figure inset was applied. The current at the end of each pulse at 100 mV (blue) and −60 mV (black) is shown. (B) Time course of current inhibition (mean ± SEM) upon initiation of the VSP activation protocol for TRPV1-WT (black, *n* = 5) and TRPV1-R721A (red, *n* = 10). (C) All-points plots representing the current remaining at −60 mV after 90 s of applying the VSP activation voltage protocol. The red points represent the data for each patch, and the black points with whiskers represent the mean ± SEM. The numbers in parentheses denote the number of patches for each condition. The asterisk indicates there is a significant difference between the two conditions (Mann--Whitney *U* test, two-tailed, P ≤ 0.01).](JGP_201511354_Fig4){#fig4}

In excised patches from control cells in which VSP was not expressed, depolarizing steps produced little, if any, change in the capsaicin-activated currents for both WT TRPV1 ([Fig. 4 A](#fig4){ref-type="fig"}, top left) and TRPV1-R721A ([Fig. 4 A](#fig4){ref-type="fig"}, bottom left). In excised patches from cells in which VSP was coexpressed with TRPV1-WT, the VSP-activating depolarizations reduced the capsaicin-activated current ([Fig. 4](#fig4){ref-type="fig"}, A \[top right\], B, and C), as previously reported ([@bib23]). In excised patches from cells coexpressing VSP with TRPV1-R721A and subjected to the VSP-activating voltage protocol, the fraction of the initial current remaining at the end of the VSP-activating protocol (I/I~initial~) was significantly different for TRPV1-R721A compared with TRPV1-WT ([Fig. 4](#fig4){ref-type="fig"}). This was not caused by VSP-independent differences between TRPV1-R721A and TRPV1-WT, as no difference in the effects of the VSP-activating protocol on I/I~initial~ was observed in cells that were not transfected with VSP ([Fig. 4 C](#fig4){ref-type="fig"}).

Our demonstration that conversion of PI(4,5)P~2~ to PI(4)P by activation of a VSP gave significantly attenuated inhibition of TRPV1-R721A compared with WT TRPV1 is consistent with the hypothesis that PI(4)P can support channel activity in patches from cells expressing mutant channels. Although beyond the scope of this manuscript, the much smaller run down of activity observed in TRPV1-R721A upon activation of VSP may be a clue to the role that PI(4)P plays in TRPV1 physiology (see Discussion). However, it is possible that the run down observed with TRPV1-R721A could be the result of endogenous 4′ phosphatase activity in the patches that was not apparent until implementation of the VSP activation protocol also reduced the concentration of PI(4,5)P~2~.

VSP allowed us to look at the effects of changes in phosphoinositide selectivity with endogenous lipids already present in the patch, without the need of initially adding PolyK to remove lipids bound to the channel or using synthetic, short-chain versions of PI(4)P and PI(4,5)P~2~. Importantly, the VSP data are consistent with the inverted phosphoinositide selectivity observed in the dose--response relationships for PI(4)P and PI(4,5)P~2~, supporting the hypothesis that R721 comprises part of the PI(4,5)P~2~-binding site.

TRPV1-WT and TRPV1-R721A are inhibited to different levels when PI(4,5)P~2~ is dephosphorylated to PI(4)P by a chemically inducible lipid phosphatase in the context of a whole cell
------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Because a point mutation that inverts the phosphoinositide selectivity was unprecedented, we next sought confirmation that the mutation would have the same effect in the context of a whole cell. We used a chemically inducible phosphatase that, like VSP, dephosphorylates PI(4,5)P~2~ to form PI(4)P. In response to application of the small molecule rapamycin, a soluble domain fused to a lipid phosphatase dimerizes with a membrane-anchored domain. Recruitment of the lipid phosphatase to the plasma membrane effectively induces activity by bringing and locking the phosphatase at the plasma membrane where it can access PI(4,5)P~2~ for dephosphorylation ([@bib46]; [@bib49]). This phosphatase is believed to be highly selective for PI(4,5)P~2~, at least in vitro, such that its recruitment to the plasma membrane is not expected to cause detectable depletion of PI(4)P.

We have used this system previously to demonstrate a temporal correlation between depletion of membrane PI(4,5)P~2~ and inhibition of TRPV1-WT capsaicin-activated currents ([@bib23]). In the current study we used the same approach to compare the effect that the conversion of PI(4,5)P~2~ into PI(4)P has on TRPV1-WT and TRPV1-R721A capsaicin-activated currents in whole cells. For these experiments, we transiently transfected HEK 293T/17 cells with the rapamycin system (membrane-tethered receptor and phosphatase fusion), the fluorescently labeled PI(4,5)P~2~ probe PH-YFP (the PH domain from phospholipase C δ1 fused to YFP; [@bib25]), and either TRPV1-WT or TRPV1-R721A. HEK293T/17 cells were used instead of F-11 cells because of the exceptional ease of transfecting HEK293T/17 cells with multiple cDNAs. Cells were voltage-clamped under the perforated patch whole-cell configuration and held at −60 mV for the duration of the experiment, while simultaneously imaged with a confocal microscope. These conditions allowed us make electrophysiological recordings of TRPV1 activity and simultaneously track changes in PI(4,5)P~2~ levels by monitoring PH-YFP.

[Fig. 5 A](#fig5){ref-type="fig"} shows representative experiments for TRPV1-WT and TRPV1-R721A. For each type of channel, the whole-cell current is shown as black points. Upon addition of 1 µM capsaicin to the bath (for the duration indicated by the black bar), both types of channels were activated, giving a large increase in the current. The mean fluorescence intensity caused by PH-YFP from a cytosolic region of interest was taken as a reflection of the PI(4,5)P~2~ level in the plasma membrane and plotted with yellow points. Because of the relatively high concentrations of PI(4,5)P~2~ and PI(4)P expected at rest, PH-YFP localized to the plasma membrane at the beginning of the experiment, giving low values for cytosolic fluorescence. The addition of capsaicin did not alter PH-YFP localization because of the nominally Ca^2+^-free solution in the bath. Upon addition of rapamycin to the bath, however, the PH-YFP dissociated from the plasma membrane as PI(4,5)P~2~ was converted to PI(4)P, giving an increase in the cytosolic fluorescence ([Fig. 5 A](#fig5){ref-type="fig"}, images labeled "3" and graphs). For TRPV1-WT, the translocation of PH-YFP from the plasma membrane to the cytosol was accompanied by a reduction in the capsaicin-activated current ([Fig. 5 A](#fig5){ref-type="fig"}, left graph). In contrast, a much smaller and delayed reduction of the capsaicin-activated current was observed for TRPV1-R721A ([Fig. 5 A](#fig5){ref-type="fig"}, right graph). The collected data shown in [Fig. 5 B](#fig5){ref-type="fig"} indicate that, although the rapamycin-induced translocation of PH-YFP, and presumably depletion of PI(4,5)P~2~, was not different for TRPV1-WT and TRPV1-R721A, a significant attenuation of channel inhibition was observed in TRPV1-R721A compared with TRPV1-WT. These data indicate that even after PI(4,5)P~2~ was depleted in the plasma membrane, sufficient PI(4)P remained to support activity in TRPV1-R721A. Although metabolism of PI(4)P and PI(4,5)P~2~ in the plasma membrane have been shown to be fairly independent of one another ([@bib15]), the small, delayed decrease in TRPV1-R721A activity upon rapamycin induction of PI(4,5)P~2~ phosphatase indicates that phosphoinositide metabolism and/or TRPV1 regulation may be more complex than imagined.

![Depletion of PI(4,5)P~2~ by the rapamycin-induced phosphoinositide phosphatase gives less inhibition in TRPV1-R721A channels than in TRPV1-WT. (A) Representative experiments of simultaneous electrophysiological and confocal imaging recordings on HEK 293T/17 cells expressing TRPV1-WT (left) or TRPV1-R721A (right) with the chemically inducible phosphatase expression system. The PH-YFP fluorescence images are shown, and the numbers illustrate when in the current time course below the images were taken. The graphs show the perforated patch whole-cell currents at −60 mV (left axis, black circles) overlaid with the simultaneous fluorescence measurement in a region of interest of the cytosol in the patched cell (right axis, yellow circles). The bars above the graph represent when additions were made. The red to blue bar below the data are a cartoon to help the reader visualize how PI(4,5)P~2~ and PI(4)P levels in the plasma membrane are changing during the experiments, based on the observed translocation of the PH-YFP fluorescent PI(4,5)P~2~ probe. Currents were activated by 1 µM capsaicin (black bars) in nominally Ca^2+^-free solution. Once current activation reached steady-state, 1 µM rapamycin (green bars) was added to induce phosphatase localization to the plasma membrane and therefore dephosphorylation of plasma membrane PI(4,5)P~2~, its depletion tracked by the movement of PH-YFP. (B) Data representation in the box plots is as in [Fig. 3](#fig3){ref-type="fig"}. (left) Box plot of the capsaicin-activated current left after complete PH-YFP translocation to the cytosol (representing depletion of plasma membrane PI(4,5)P~2~) for TRPV1-WT and TRPV1-R721A. The asterisk indicates a statistically significant difference (P \< 0.001). For both TRPV1-WT and TRPV1-721A, seven cells were included in the analysis. (right) Box plot comparing PH-YFP translocation in TRPV1-WT and TRPV1-R721A cells. Translocation index was calculated as cytosolic fluorescence after PH-YFP translocation has stopped, divided by the initial cytosolic fluorescence. For both TRPV1-WT and TRPV1-721A, seven cells were included in the analysis. The meaning of the boxes and whiskers is the same as in [Fig. 4](#fig4){ref-type="fig"}.](JGP_201511354_Fig5){#fig5}

Correcting for partition coefficients shows an even greater selectivity of WT TRPV1 for PI(4,5)P~2~ compared with PI(4)P
------------------------------------------------------------------------------------------------------------------------

The apparent selectivity of TRPV1 for PI(4,5)P~2~ over PI(4)P could be inaccurate, or even misleading, if the two phosphoinositides partition into the membrane differently. Indeed, one would expect the less-charged diC8-PI(4)P to partition into the membrane more strongly than the more-charged diC8-PI(4,5)P~2~ ([@bib9]). Thus, at the same solution concentrations, there may be different amounts of each phosphoinositide in the membrane.

We recently measured the relationship between the solution concentrations of diC8-PI(4)P and diC8-PI(4,5)P~2~ and their mole fractions in the plasma membrane ([@bib9]). These measurements allowed us to replot the data shown in [Fig. 2 D](#fig2){ref-type="fig"} in terms of the mole fractions of PI(4)P and PI(4,5)P~2~ in the inner leaflet of the plasma membrane ([Fig. 2 E](#fig2){ref-type="fig"}). From these plots, we estimated the EC~50~ for TRPV1-WT to be ∼0.03 mol % for diC8-PI(4,5)P~2~ and ∼1 mol % for diC8-PI(4)P and for TRPV1-R721A to be ∼0.04 mol % for diC8-PI(4,5)P~2~ and ∼0.007 mol % for diC8-PI(4)P.

DISCUSSION
==========

Nearly every aspect of TRPV1 regulation by phosphoinositides is controversial. PI(4,5)P~2~ has been proposed to inhibit TRPV1, mediating the sensitizing actions of bradykinin and nerve growth factor ([@bib8]; [@bib4]). In contrast, others (including us) have proposed that PI(4,5)P~2~ activates TRPV1 ([@bib44]; [@bib28], [@bib29]; [@bib23]), and the depletion of PI(4,5)P~2~ by phospholipase C may play a role in Ca^2+^-dependent desensitization ([@bib31]; [@bib30]). However, a recent study measured the apparent affinity of TRPV1 for diC8-PI(4,5)P~2~ and found that the activating effects occurred with a K~1/2~ of only ∼0.03 mol % in the plasma membrane, raising the question of whether PI(4,5)P~2~ levels in the plasma membrane ever get sufficiently low for TRPV1 to lose its bound PI(4,5)P~2~ ([@bib9]).

Disagreement about PI(4,5)P~2~ regulation of TRPV1 extends to the localization of its binding sites in the channel's primary sequence. Candidate binding sites in the conserved proximal C-terminal region ([@bib47]) and the nonconserved distal C-terminal region ([@bib37]; [@bib4]) have been proposed ([Fig. 1 A](#fig1){ref-type="fig"}), with a variety of evidence supporting the involvement of each region. This controversy has continued, at least in part, because demonstrating direct interactions between a lipid and a functional membrane protein in a native environment is exceedingly difficult. No one gold standard approach exists.

Here we report that the single-point mutation R721A, contained within the candidate PI(4,5)P~2~-binding site in the proximal C-terminal region of TRPV1, switched the efficacy of PI(4,5)P~2~ and PI(4)P to activate capsaicin-activated currents. This mutation made PI(4,5)P~2~ less effective at activating capsaicin-activated currents, at the same time making PI(4)P a more efficient agonist. We consider this finding a strong indicator that residue R721 lies within the region of the channel that directly interacts with phosphoinositides.

Our data implicating the proximal C-terminal region of TRPV1 as a site of direct interaction with phosphoinositides can be interpreted in light of the high-resolution structure of TRPV1 recently determined using cryo-electron microscopy ([Fig. 1 A](#fig1){ref-type="fig"}; [@bib5]; [@bib26]). The protein used in these structural studies involved a truncation of the distal C terminus. The proximal C terminus, although present, was resolved only until about residue 719, just shy of the arginine whose role in phosphoinositide regulation we describe here. However, the region between the bottom of the S6 membrane-spanning domain and R721 appears to be an α-helical segment arranged supine along where the surface of the lipid bilayer is expected to be. Given that any region of sequence that interacts directly with a phospholipid head group must be in close proximity of the bilayer, the sequence leading up to R721 conforms to expectations.

Regulation of TRPV1 by phosphoinositides has been proposed to involve not just PI(4,5)P~2~ but also PI(4)P. Using either PI(4,5)P~2~- or PI(4)P-specific phosphatases fused to the rapamycin-inducible FKBP construct, TRPV1 expressed in Cos-7 cells was found to be inhibited only when both phosphatases were translocated to the plasma membrane ([@bib15]). In addition, specific dephosphorylation of PI(4,5)P~2~ by a VSP in whole-cell patch-clamp experiments with HEK293 cells transfected with TRPV1 showed that the VSP did not inhibit TRPV1 activity induced by extracellular protons although it inhibited Kir2.1 channels in the same cells ([@bib30]). Together these data suggest that, even in TRPV1-WT, PI(4)P may play a role in maintaining TRPV1 activity, at least under conditions in which PI(4,5)P~2~ levels decrease. Teasing apart the contributions of PI(4)P and PI(4,5)P~2~ in the R721A mutant, in which PI(4)P is a better activator than PI(4,5)P~2~, would require a better understanding of the roles the two phosphoinositides play in WT TRPV1. In addition, phosphoinositide levels are known to influence membrane trafficking, cytoskeleton proteins, and protein kinases/phosphatases. Whether there are downstream regulatory changes that occur selectively with PI(4)P- or PI(4,5)P~2~-bound TRPV1 has yet to be addressed. However, phosphoinositide-selective regulation is one way in which the run down of TRPV1-R721A we observed with activation of the phosphatase by VSP ([Fig. 4](#fig4){ref-type="fig"}) or rapamycin ([Fig. 5](#fig5){ref-type="fig"}) could occur.

It is worth noting that our attempts to fit a simple kinetic model to our VSP data (not depicted) did not yield insight into why VSP would produce a decay of the capsaicin-activated current in the PI(4)P-preferring TRPV1-R721A. Indeed, given that VSP's enzymatic activity produces PI(4)P from PI(4,5)P~2~ ([@bib14]), it might be expected that TRPV1-R721A currents would not run down in response to VSP activation. Our finding that VSP inhibits TRPV1-R721A therefore speaks to the complexity of phosphoinositide signaling networks in cells. Deconvolving the direct effects of changing phosphoinositide levels from downstream effects will require extensive future work.

We originally examined the R721A mutation because we expected neutralization of a positive amino acid side chain to disrupt phosphoinositide regulation of TRPV1. Instead, we found that, considering the small, nonspecific effect of the mutation on gating, both PI(4,5)P~2~ and PI(4)P seem potentiated relative to WT, with a disproportionate potentiation of PI(4)P. The change in selectivity might be expected, in that the R to A mutation might disrupt interactions with two phosphates on PI(4,5)P~2~ and with only one phosphate on PI(4)P. However, an increase in apparent affinity rather than a decrease cannot be easily explained. These results highlight the need for structural studies that include the lipid bilayer to elucidate the specific chemical interactions between TRPV1 and the signaling lipids that regulate it.

Perhaps the most important conclusion from our data is that an electrostatic cloud mechanism for interaction between TRPV1 and phosphoinositides, such as is observed for the MARCKS protein, cannot account for our data. For MARCKS and other polybasic phosphoinositide-binding domains, the primary recognition of PI(4,5)P~2~ is based on charge density; such proteins always interact more strongly with doubly phosphorylated phosphoinositides compared with singly phosphorylated phosphoinositides. Furthermore, a point mutation that increases the EC~50~ for PI(4,5)P~2~ by 30% yet decreases the EC~50~ for PI(4)P by over two orders of magnitude indicates that the molecular basis for phosphoinositide selectivity must involve multiple, specific interactions between TRPV1 and the phosphoinositide ligand. Whether the intimate contacts that allow TRPV1 to discern whether a phosphate or hydroxyl occupies the 5′ position on the inositol ring are a common theme among phosphoinositide-regulated ion channels remains to be determined.
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